EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 1st, 2019 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • California
Employment Agreement (“Agreement”) made as of the 17th day of January, 2018 by and between Sangamo Therapeutics, Inc., a Delaware corporation (the “Company”), and Heather Turner (“Executive”) (2collectively, the “Parties”).
FIRST AMENDMENT TO LEASE AGREEMENT BETWEEN MARINA BOULEVARD PROPERTY, LLC ANDLease Agreement • March 1st, 2019 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances)
FIFTH AMENDMENT TO LEASELease • March 1st, 2019 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances)
THIS FIFTH AMENDMENT TO LEASE (this ''Fifth Amendment") is entered into as of July 10, 2017 (the "Effective Date"), by and between POINT RICHMOND R&D ASSOCIATES II, LLC, a California limited liability company ("Landlord"), and SANGAMO THERAPEUTICS, INC., a Delaware corporation (formerly known as Sangamo Biosciences, Inc., a Delaware corporation) ("Tenant"), with reference to the following facts:
FOURTH AMENDMENT TO LEASELease ( • March 1st, 2019 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances)
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 1st, 2019 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • California
Employment Agreement (“Agreement”) made as of the 18th day of November, 2018 by and between Sangamo Therapeutics, Inc., a Delaware corporation (the “Company”), and Adrian Woolfson (“Executive”) (collectively, the “Parties”).
